<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3574">
  <stage>Registered</stage>
  <submitdate>3/05/2012</submitdate>
  <approvaldate>3/05/2012</approvaldate>
  <nctid>NCT01622088</nctid>
  <trial_identification>
    <studytitle>Phase 3 Extension Study of Dexpramipexole in ALS</studytitle>
    <scientifictitle>An Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Dexpramipexole (BIIB050) in Subjects With Amyotrophic Lateral Sclerosis</scientifictitle>
    <utrn />
    <trialacronym>ENVISION</trialacronym>
    <secondaryid>EUDRA CT #: 2011-006119-70</secondaryid>
    <secondaryid>223AS304</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Amyotrophic Lateral Sclerosis</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Neurodegenerative diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Dexpramipexole

Experimental: Dexpramipexole - 


Treatment: drugs: Dexpramipexole
Oral tablet 150 mg given twice daily up to 36 months

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence of Adverse Events and Serious Adverse Events</outcome>
      <timepoint>36 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Discontinuation of study treatment due to an Adverse Events</outcome>
      <timepoint>36 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight</outcome>
      <timepoint>36 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Incidence of laboratory abnormalities</outcome>
      <timepoint>36 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score</outcome>
      <timepoint>36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Decline in sniff nasal inspiratory pressure (SNIP)</outcome>
      <timepoint>36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to death</outcome>
      <timepoint>36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for = 22 hours per day for = 10 days)</outcome>
      <timepoint>36 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Subject has the ability to understand the purpose and risks of the study and provide
             signed and dated informed consent (or have the consent confirmed by a witness if
             unable to write) and authorization to use protected health information (PHI) in
             accordance with national and local subject privacy regulations.

          -  Subject was enrolled in either CL211 (NCT00931944) or Study 223AS302 (NCTO1281189).

          -  Subject has completed their last visit in Study CL211 (NCT00931944) or Study 223AS302
             (NCTO1281189).

          -  Subjects of childbearing potential must practice effective contraception during the
             study and be willing and able to continue contraception for 1 month (females) or 3
             months (males) after their last dose of study treatment.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Subject withdrew prematurely from Study CL211 (NCT00931944) or Study 223AS302
             (NCTO1281189).

          -  Subject permanently discontinued study treatment in Study CL211 (NCT00931944) or Study
             223AS302 (NCTO1281189) for any reason other than enrollment into this study.

          -  Subject from Study CL211 (NCT00931944) or Study 223AS302 (NCTO1281189) has a
             significant change in medical history (including laboratory tests or a clinically
             significant condition) that in the opinion of the Investigator would impair the
             subject's medical fitness for participation and preclude treatment.

          -  Female subject who is pregnant or breastfeeding.

          -  Subject is currently enrolled in any investigational drug study other than Study CL211
             (NCT00931944) or Study 223AS302 (NCTO1281189).

          -  Subject is taking pramipexole, other dopamine agonists, any other agent with
             dopaminergic activity, or any other disallowed concomitant medication.

          -  Subject is unwilling or unable to comply with the requirements of the protocol
             including the presence of any condition (physical, mental, or social) that is likely
             to affect the subject's ability to comply with the protocol. At a minimum, subjects
             who are not able to travel to the study site must be willing to agree to remote blood
             draws for clinical laboratory evaluations and telephone visits to report Adverse
             Events, concomitant medications, and Amyotrophic Lateral Sclerosis Functional Rating
             Scale (revised) (ALSFRS-R) scores.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>616</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/02/2013</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC</recruitmentstate>
    <hospital>Prince of Wales Hospital - Randwick</hospital>
    <hospital>Westmead Hospital - Westmead</hospital>
    <hospital>Royal Brisbane and Women's Hospital - Herston</hospital>
    <hospital>Calvary Health Care Bethlehem - Melbourne</hospital>
    <postcode> - Randwick</postcode>
    <postcode>2145 - Westmead</postcode>
    <postcode>4029 - Herston</postcode>
    <postcode>3121 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Iowa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nevada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Hampshire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Gent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Toronto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Vancouver</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Marseille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Montpellier</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bochum</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hannover</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Jena</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Ulm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>Dublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Nijmegen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Utrecht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>GÃ¶teborg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Stockholm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Birmingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Liverpool</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Newcastle</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Oxford</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Sheffield</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Knopp Biosciences</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Biogen</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of the study is to collect long-term safety data from subjects with Amyotrophic
      Lateral Sclerosis (ALS) exposed to dexpramipexole.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01622088</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>